Synta Pharmaceuticals jumps on publication of ganetespib results


Synta Pharmaceuticals (SNTA +4.2%) moves higher in early trading.

The shares are likely getting a lift from news that collaborators at Johns Hopkins and Duke's Dana-Farber Cancer Institute have separately published results which the company says "demonstrate the ability of ganetespib to down-regulate a number of key proteins involved in tumor growth and metastasis." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs